EUCTR2005-004504-36-BEActive, not recruitingPhase 1
A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of Caspofungin in the Treatment of Invasive Candidiasis in Adults. - MK-0991 High Dose Study
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Merck Sharp & Dohme BV
- Enrollment
- 220
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •Clinical and microbiological (culture-proven) evidence of blood stream &/or systemic Candida infections
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •1) Possible Candida contamination
- •2) Candida colonization ( non invasive infection), or Candida involvement of urine, heart valve, ,bone, cerebral spinal fluid, or
- •prosthetic devices.
- •3) Acute or moderately severe liver disease
- •4) Abnormal liver function tests
- •5) Abnormal blood clotting for patients on blood thinners
Investigators
Similar Trials
Active, not recruiting
Not Applicable
A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of Caspofungin in the Treatment of Invasive Candidiasis in Adults.Candidiasis (invasive)EUCTR2005-004504-36-LVMerck & Co. Inc220
Active, not recruiting
Phase 1
A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of Caspofungin in the Treatment of Invasive Candidiasis in Adults. - MK-0991 High Dose StudyCandidiasis (invasive)MedDRA version: 8.0 Level: LLT Classification code 10007152EUCTR2005-004504-36-PTMerck sharp & Dohme, Lda.220
Active, not recruiting
Phase 1
A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of Caspofungin in the Treatment of Invasive Candidiasis in Adults. - MK-0991 High Dose StudyEUCTR2005-004504-36-DEMerck & Co. Inc.220
Active, not recruiting
Not Applicable
A Multicenter, Randomized, Double-Blind, Comparative Trial Of A Novel CCR5 Antagonist, UK-427,857, In Combination With Zidovudine/Lamivudine Versus Efavirenz In Combination With Zidovudine/Lamivudine For The Treatment of Antiretroviral-Naive HIV-1 Infected SubjectsHIV-1 treatment in combination with other agentsMedDRA version: 9.1Level: SOCClassification code 10021881Term: Infections and infestationsEUCTR2004-001914-15-ITPfizer LTD, Pfizer Global RD-Sandwich Laboratories-I.P.C. 5821,071
Active, not recruiting
Phase 1
A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of Caspofungin in the Treatment of Invasive Candidiasis in Adults. - MK-0991 High Dose StudyEUCTR2005-004504-36-CZMerck & Co., Inc.220